Search AI Products and News

Isomorphic Labs, a platform focused on AI-powered drug discovery, founded in 2021 as a spin-off from Google's DeepMind, has secured $600 million in Series A funding led by Thrive Capital, with participation from GV and existing investor Alphabet (Google's parent company). This funding will accelerate the further development of Isomorphic's AI drug design engine and support the company's R&D efforts.

Google recently announced the launch of its new open-source model, TxGemma, designed to significantly improve the efficiency of therapeutic drug development. Developed by the Google DeepMind team, this model is a fine-tuned version of their advanced Gemma model family, incorporating powerful natural language understanding, scientific prediction, and multi-turn dialogue capabilities. TxGemma aims to revolutionize drug discovery. Its release is considered a significant advancement in the application of AI to biomedicine, promising to drastically shorten the time it takes for drugs to move from the lab to clinical trials, while also reducing costs.

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.

Recently, former DeepMind scientist Simon Kohl announced the establishment of a new artificial intelligence drug discovery company, aiming to leverage his extensive experience in protein prediction, particularly related to the Nobel Prize-winning AlphaFold system. AlphaFold is a revolutionary AI tool that can accurately predict the three-dimensional structure of proteins, a breakthrough that has garnered significant attention in biomedical research. Image source note: Image generated by AI, image licensed service.

🧪 Drug Discovery Process: The article mentions that it takes an average of 6 years for a drug to go from discovery to clinical trial phase. 📈 AI Companies Claim: AI startups claim that their drug candidate compounds have shortened the time from discovery to clinical trials to under 10 years, with some individual cases taking only 30 months. 🧐 Caution is Advised: These claims lack independent third-party verification, as clinical trials are necessary to test their feasibility.